CoChat

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Background Atezolizumab is an inhibitor of PD-L1, which can lead to enhanced anticancer T-cell activity. We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in children and young adults with refractory or relapsed solid tumours, with known or expected PD-L1 expression.Methods iMATRIX was a multicentre, open-label, phase 1-2 trial of patients (aged <30 years) with solid tumours or lymphomas recruited from 28 hospitals in ten countries (USA, France, Italy, UK, Spain, the Netherlands, Denmark, Israel, Switzerland, and Germany). Eligible patients younger than 18 years received 15 mg/kg atezolizumab (maximum 1200 mg); patients aged 18-29 years received the adult dose (1200 mg) until disease progression or loss of clinical benefit. Co-primary endpoints were safety (assessed by incidence of adverse events) and pharmacokinetics (assessed by serum atezolizumab concentrations). Secondary endpoints included the proportion of patients achieving an objective response. This trial is registered with ClinicalTrials.gov, number NCT02541604.Findings Between Nov 5, 2015, and April 2, 2018, we screened 115 patients, 25 of whom did not meet the inclusion criteria. 90 patients, with a median age of 14 years (IQR 10-17), were enrolled. At the data cutoff (April 2, 2018), two patients remained on study treatment. 87 (97%) of 90 patients received at least one dose of atezolizumab at 15 mg/kg or 1200 mg and were evaluable for safety. Three patients were not treated owing to either poor clinical condition or withdrawal of consent. In the safety-evaluable population (n=87), the most common adverse events were pyrexia (36 [41%] patients) and fatigue (31 [36%]). The most common grade 3-4 adverse event was anaemia (19 [22%] patients). The most commonly reported serious adverse events were in the categories of infections and infestations; pyrexia was the only serious adverse event reported in more than two patients. 57 (66%) patients had at least one treatment-related adverse event (grade 1-4); fatigue was the most common treatment-related adverse event (17 patients [20%]). There were no fatal adverse events. Mean serum concentrations of atezolizumab were overlapping and comparable between children receiving 15 mg/kg and young adults receiving 1200 mg of atezolizumab every 3 weeks. Serum concentrations of atezolizumab were above the target exposure level in all patients. At 6 months, four patients (5%) achieved an objective response (all partial responses).Interpretation Although response to atezolizumab was restricted, atezolizumab was well tolerated with generally comparable exposure across populations. Our findings might help to define future development strategies for immune checkpoint inhibitors either by focusing research to specific disease subpopulations that exhibit greater benefit from immune checkpoint inhibitors, or by providing the means to identify therapeutic combination partners that augment T-cell infiltration and proliferation in so-called immune cold tumour microenvironments.Funding F Hoffmann-La Roche.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30693-x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 171

Metadata

Authors
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., Hutchinson, K. E., Donaldson, F., Liao, M., Caron, H., & Trippett, T.
Affiliations
  • Université Paris-Saclay (FR)
  • Princess Máxima Center (NL)
  • Royal Marsden NHS Foundation Trust (GB)
  • Institut Curie (FR)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Centre Léon Bérard (FR)
  • F. Hoffmann-La Roche AG (CH)
  • Genentech (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Geoerger, Birgit
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-01
Volume
21
Issue
1
Pages
134-144
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2990849834
Cited by
171
References
34
Citations by year
2026: 17 · 2025: 21 · 2024: 28 · 2023: 36 · 2022: 31 · 2021: 25 · 2020: 10
FWCI
7.21
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Funders
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • School of Medicine, Stanford University
  • F. Hoffmann-La Roche
  • Penn State Health Children&apos;s Hospital
  • Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
atezolizumab, PD-L1 inhibitors, children and young adults, solid tumors, non-Hodgkin lymphoma, Hodgkin's disease, pharmacokinetics, safety, objective response, immune-related adverse events, fever, anemia, immunotherapy, PD-L1 expression, T cell function, dose-limiting toxicity
MeSH terms
Adolescent, Adult, Antineoplastic Agents, Child, Child, Preschool, Female, Follow-Up Studies, Hodgkin Disease, Humans, Lymphoma, Non-Hodgkin, Male, Neoplasms, Prognosis, Tissue Distribution, Maximum Tolerated Dose, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30693-x
The paper
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., Hutchinson, K. E., Donaldson, F., Liao, M., Caron, H., & Trippett, T. (2020). Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30693-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.